These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38199791)

  • 21. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
    Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The CCL27-CCR10 axis contributes to promoting proliferation, migration, and invasion of lung squamous cell carcinoma.
    Li B; Wei C; Zhong Y; Huang J; Li R
    Histol Histopathol; 2023 Mar; 38(3):349-357. PubMed ID: 36169116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.
    Shin DH; Min HY; El-Naggar AK; Lippman SM; Glisson B; Lee HY
    Mol Cancer Ther; 2011 Dec; 10(12):2437-48. PubMed ID: 21980128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance.
    Yang M; Lin C; Wang Y; Chen K; Zhang H; Li W
    Genome Med; 2022 Jul; 14(1):72. PubMed ID: 35799269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LncRNA LINC00649 recruits TAF15 and enhances MAPK6 expression to promote the development of lung squamous cell carcinoma via activating MAPK signaling pathway.
    Zhu H; Liu Q; Yang X; Ding C; Wang Q; Xiong Y
    Cancer Gene Ther; 2022 Aug; 29(8-9):1285-1295. PubMed ID: 35228660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment of a prognostic model toward lung squamous cell carcinoma based on m
    Wang Y; Liu Y; Wang R; Cao F; Guan Y; Chen Y; An B; Qin S; Yao S
    Physiol Genomics; 2023 Oct; 55(10):427-439. PubMed ID: 37575065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction and Validation of Prognostic Regulation Network Based on RNA-Binding Protein Genes in Lung Squamous Cell Carcinoma.
    Zhao S; Liu Q; Li J; Hu C; Cao F; Ma W; Gao J
    DNA Cell Biol; 2021 Dec; 40(12):1563-1583. PubMed ID: 34931870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
    Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
    Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Target and Mechanism of the Xihuang Pill Based on Network Pharmacology for Lung Squamous Cell Carcinoma.
    Tu H; Li J; Xu W; Wang Z; Wang L
    Altern Ther Health Med; 2023 Oct; 29(7):148-154. PubMed ID: 37442189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
    Exposito F; Redrado M; Houry M; Hastings K; Molero-Abraham M; Lozano T; Solorzano JL; Sanz-Ortega J; Adradas V; Amat R; Redin E; Leon S; Legarra N; Garcia J; Serrano D; Valencia K; Robles-Oteiza C; Foggetti G; Otegui N; Felip E; Lasarte JJ; Paz-Ares L; Zugazagoitia J; Politi K; Montuenga L; Calvo A
    Cancer Res; 2023 Aug; 83(15):2513-2526. PubMed ID: 37311042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a glycolysis-related gene signature associated with clinical outcome for patients with lung squamous cell carcinoma.
    Xu Z; Zhang S; Nian F; Xu S
    Cancer Med; 2021 Jun; 10(12):4017-4029. PubMed ID: 33991070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
    Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
    J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Clinical Prognostic Regulators and Analysis of Ferroptosis-Related Signatures in the Tumor Immune Microenvironment in Lung Squamous Cell Carcinoma.
    Wang W; Cui G; Zhao S
    Dis Markers; 2023; 2023():9155944. PubMed ID: 36845013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-derived KLK8 predicts inferior survival and promotes an immune-suppressive tumor microenvironment in lung squamous cell carcinoma.
    Tian H; Wei R; Xiao C; Fan T; Che Y; Liu T; Zheng B; Li C; He J
    BMC Pulm Med; 2024 Jan; 24(1):53. PubMed ID: 38273291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway.
    Wang S; Cheng Z; Cui Y; Xu S; Luan Q; Jing S; Du B; Li X; Li Y
    J Transl Med; 2023 Nov; 21(1):819. PubMed ID: 37974250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
    Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR; Sun SY
    J Biol Chem; 2013 May; 288(19):13215-24. PubMed ID: 23536185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific Lung Squamous Cell Carcinoma Prognosis-Subtype Distinctions Based on DNA Methylation Patterns.
    Huang G; Zhang J; Gong L; Liu D; Wang X; Chen Y; Guo S
    Med Sci Monit; 2021 Mar; 27():e929524. PubMed ID: 33661858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of immune subtypes and overall survival in lung squamous cell carcinoma.
    Su X; Gao H; Qi Z; Xu T; Wang G; Luo H; Cheng P
    Curr Med Res Opin; 2023 Feb; 39(2):289-298. PubMed ID: 36245361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of T-cell cytotoxic marker IL18R1 promotes cancer proliferation and migration and is associated with dismal prognosis and immunity in lung squamous cell carcinoma.
    Guo Q; Wu CY; Jiang N; Tong S; Wan JH; Xiao XY; Mei PY; Liu HS; Wang SH
    Front Immunol; 2022; 13():986447. PubMed ID: 36544782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.